Latest Conference Articles

New data from the ONS Congress suggest that chemotherapy-induced peripheral neuropathy may persist for years in survivors of frontline lymphoma care.

A UAMS study shows non-musical sound machines significantly reduce patient anxiety during gynecology oncology appointments in a cost-effective way.

Both pre- and post-evidence–based practice change occlusion rates were low with relation to anticipated rates among hospitalized adult patients with cancer.

Jill Winther earned the 2026 Extraordinary Healer® Award for her leadership, advocacy and dedication to oncology nursing.

At SGO 2026, the BEHOLD-1 trial revealed a 62% ORR for mocertatug rezetecan in PROC, offering a manageable new ADC option for oncology nurses to track.

1INSPIRE data at SGO 2026 confirms frontline niraparib (Zejula) has a manageable safety profile with low discontinuation rates in ovarian cancer.

Mirvetuximab soravtansine shows 16.4-month OS in ovarian cancer, though poor ECOG status and toxicity significantly impact life expectancy.

Data at SGO 2026 showed gynecologic cancer survivors face high rates of untreated LUTS and missed radiation cystitis diagnoses after treatment.

Phase 3 trial results show letrozole monotherapy is not noninferior to chemotherapy followed by hormone therapy for patients with advanced LGSOC.

New phase 2 data confirms the Avmapki Fakzynja Co-pack offers lasting efficacy and stable safety for patients with recurrent KRAS-mutated LGSOC.

Phase 3 ROSELLA data shows relacorilant and nab-paclitaxel reduced death risk by 35% in platinum-resistant ovarian cancer, a new preferred treatment.

The SISTER trial finds 1:1 peer support significantly improves endometrial cancer treatment completion for Black women, per 2026 SGO Meeting data.

Eliya Shachar, UCLA Health, says toxicity risk is not independently tied to age or demographics, reinforcing consistent monitoring and individualized care for all patients.

Nurses can catch early IO toxicities through routine symptom checks and support long-term care, as effects may persist after treatment ends.

Zongertinib elicited responses in patients with advanced HER2-mutant NSCLC, showing intracranial efficacy in those with active brain metastases, per phase 1b Beamion LUNG-1 data.

Adagrasib shows efficacy in elderly patients with KRAS G12C-mutant NSCLC and an ECOG PS of 0-1, while those with a PS of 2 see limited survival benefit but QOL improvements.

Calderasib, a potent KRAS G12C inhibitor, demonstrated improved outcomes in patients with metastatic NSCLC, especially when combined with pembrolizumab.

Explore phase 1 data for setidegrasib, a novel KRAS G12D-targeted protein degrader showing antitumor activity and manageable infusion-related reactions in patients with advanced NSCLC.

Research presented at the APOS Conference demonstrated negative beliefs in parents and caregivers of pediatric patients with cancer.

Amber Altidor, NP, shares how oncology nurses can use teach-back methods and learning style assessments to improve patient education on medication toxicities.

Data presented at the annual APOS Conference revealed training and workflow issues in providing developmentally appropriate cancer care to AYA patients.

Patients younger than 40 experience higher rates of CINV and more commonly use marijuana, diet changes, and other methods to manage symptoms.

Radiation-induced heart damage in breast cancer is a growing clinical concern, yet biomarkers and preventive therapies remain lacking.

A multidisciplinary approach to care is key when addressing sexual health concerns among breast cancer survivors.

Mark S. Lin, MSN, FNP-BC, highlighted nursing considerations for breast reconstruction surgery in breast cancer.

Lillian Rodich, PA-C, MPH, stressed that nurses can take advantage of accessible and local integrative medicine resources to treat patients with cancer.

Don S. Dizon, MD, FACP, FASCO, shared insights on what pregnancy looks like with a breast cancer diagnosis and what those considering pregnancy should know.

Findings from real-world community clinics show favorable efficacy of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer.